Physician Wealth Advisors Inc. purchased a new position in shares of Everus (NYSE:ECG – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,125 shares of the company’s stock, valued at approximately $74,000.
Other institutional investors have also modified their holdings of the company. SRS Capital Advisors Inc. bought a new position in Everus in the 4th quarter worth about $26,000. Principal Securities Inc. bought a new position in Everus in the 4th quarter worth approximately $27,000. HighMark Wealth Management LLC acquired a new stake in Everus in the 4th quarter valued at approximately $28,000. Crews Bank & Trust bought a new stake in Everus during the 4th quarter valued at $29,000. Finally, Mendota Financial Group LLC acquired a new position in Everus during the 4th quarter worth $36,000.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on ECG shares. Stifel Nicolaus lowered their price target on Everus from $85.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Wolfe Research assumed coverage on shares of Everus in a research report on Tuesday, December 3rd. They set a “peer perform” rating on the stock. Finally, Oppenheimer upped their price target on shares of Everus from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 7th.
Insider Buying and Selling
In related news, CFO Maximillian J. Marcy acquired 1,300 shares of Everus stock in a transaction dated Tuesday, February 25th. The stock was acquired at an average cost of $38.99 per share, with a total value of $50,687.00. Following the purchase, the chief financial officer now directly owns 5,508 shares in the company, valued at $214,756.92. The trade was a 30.89 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward A. Ryan bought 1,400 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was bought at an average price of $38.02 per share, for a total transaction of $53,228.00. Following the completion of the acquisition, the director now directly owns 14,928 shares in the company, valued at approximately $567,562.56. The trade was a 10.35 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 3,750 shares of company stock worth $153,853 in the last ninety days.
Everus Price Performance
ECG opened at $36.11 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.50 and a current ratio of 1.58. The stock has a fifty day moving average price of $51.30. Everus has a one year low of $33.90 and a one year high of $77.93.
Everus (NYSE:ECG – Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported $0.67 EPS for the quarter, missing the consensus estimate of $0.73 by ($0.06). As a group, equities research analysts predict that Everus will post 2.49 earnings per share for the current fiscal year.
About Everus
Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.
Featured Stories
- Five stocks we like better than Everus
- What is Forex and How Does it Work?
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- How to Calculate Stock Profit
- MarketBeat Week in Review – 03/24 – 03/28
- Using the MarketBeat Dividend Tax Calculator
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for Everus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everus and related companies with MarketBeat.com's FREE daily email newsletter.